T-cell acute lymphoblastic leukaemia after liver transplantation: post-transplant lymphoproliferative disorder or coincidental de novo leukaemia?

Abstract:

:Post-transplant lymphoproliferative disorders of T-cell origin are quite uncommon, and the vast majority represent neoplasms of mature, post-thymic T- or natural killer cells. Here, we report a rare case of T-cell acute lymphoblastic leukaemia (T-ALL), which occurred in an 18-year-old man who had undergone three liver transplants, initially for biliary atresia and subsequently for graft failure due to chronic rejection. He had received immunosuppression with cyclosporine and tacrolimus, as well as short-term treatment with OKT3. The T-ALL occurred 16 years after the first liver transplant. This case highlights the challenge for classifying rare neoplasms occurring in recipients of solid organ transplants that are currently not recognized to lie within the spectrum of post-transplant lymphoproliferative disorders. Given the long interval between the liver transplants and the development of T-ALL, a coincidental occurrence of the leukaemia cannot be ruled out. However, the potential roles of immunosuppressive therapy and other co-morbid conditions of the individual as possible risk factors for the pathogenesis of T-ALL are discussed.

journal_name

Hematol Oncol

journal_title

Hematological oncology

authors

Fang Y,Pinkney KA,Lee JC,Gindin T,Weiner MA,Alobeid B,Bhagat G

doi

10.1002/hon.2016

subject

Has Abstract

pub_date

2013-03-01 00:00:00

pages

49-53

issue

1

eissn

0278-0232

issn

1099-1069

journal_volume

31

pub_type

杂志文章
  • Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide.

    abstract::Cytokine release syndrome (CRS) is a systemic inflammatory response with aberrant immune activation and immune hyperstimulation, that leads to increased cytokine levels and inflammation. CRS has been described after antibody and cellular-based therapies. The use of posttransplant cyclophosphamide (PTCy) as graft-vs-ho...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2772

    authors: Solán L,Landete E,Bailén R,Dorado N,Oarbeascoa G,Anguita J,Díez-Martín JL,Kwon M

    更新日期:2020-10-01 00:00:00

  • Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.

    abstract::Implementation of cytarabine into induction therapy became standard of care for younger patients with mantle cell lymphoma (MCL). On the basis of its beneficial impact, many centers incorporated cytarabine at lower doses also into first-line treatments of elderly patients. We conducted a multicenter observational stud...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2483

    authors: Klener P,Fronkova E,Belada D,Forsterova K,Pytlik R,Kalinova M,Simkovic M,Salek D,Mocikova H,Prochazka V,Blahovcova P,Janikova A,Markova J,Obr A,Berkova A,Kubinyi J,Vaskova M,Mejstrikova E,Campr V,Jaksa R,Kodet R,

    更新日期:2018-02-01 00:00:00

  • Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience.

    abstract::Given the excellent results obtained with present new induction regimens in PMBL, the role of frontline ASCT is controversial. We present 71 patients with PMBL receiving induction chemotherapy, followed by ASCT as frontline therapy from the GEL-TAMO registry. Most patients presented with high-risk clinical features. A...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.858

    authors: Rodríguez J,Conde E,Gutiérrez A,García JC,Lahuerta JJ,Varela MR,Pérez C,Albo C,Caballero MD

    更新日期:2008-09-01 00:00:00

  • Hematological malignancies in the island of Sardinia, 1974-1993: age and sex distributions and temporal changes in incidence.

    abstract::We have collected, by an active retrospective survey, all the cases of hematologic malignancies (HM) newly diagnosed during the time period 1974-1993 in the resident population of Sardinia. Diagnosis was deemed valid, after consultation of clinical records, in more than 90% of the 7264 collected cases. The number of n...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.733

    authors: Broccia G,Deplano W,Dessalvi P,Giannico B,Luxi G,Chessa E,Murru A

    更新日期:2004-09-01 00:00:00

  • Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study.

    abstract::This study evaluates response-adapted treatment of chronic myelogenous leukaemia (CML) in chronic phase using molecular response criteria. bcr-abl/G6PDH ratios were assessed by Light-Cycler quantitative real-time polymerase chain reaction (PCR( in 277 peripheral blood samples from 33 patients, before and every 3 month...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.860

    authors: Neumann F,Markett J,Fenk R,Pooten M,Koch A,Bruennert D,Schimkus N,Wulfert M,Royer-Pokora B,Kronenwett R,Haas R,Gattermann N

    更新日期:2008-12-01 00:00:00

  • CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma.

    abstract::From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m2) was used in place of doxorubicin (50 mg/m2), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age was 41 years (range: 17 t...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/(sici)1099-1069(199809)16:3<117::aid-hon63

    authors: Chim CS,Kwong YL,Lie AK,Lee CK,Liang R

    更新日期:1998-09-01 00:00:00

  • A controversial issue: could a watch-and-wait policy for patients with non-Hodgkin's lymphoma clinical stage I or IE with no lymphoma left following diagnostic surgery be justified? Results of a single centre study.

    abstract:BACKGROUND:A subset of patients with non-Hodgkin's lymphoma (NHL) with clinical stage I or IE at presentation is left without other NHL localizations following surgery performed for diagnostic histology, and thus without any target lesion to judge the immediate effectiveness of immediately applied additional treatment ...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/(sici)1099-1069(199705)15:2<53::aid-hon598

    authors: Jelić S,Frim O,Gligorijević G,Gavrilović D,Manojlović N,Jovanović V,Oprić M

    更新日期:1997-05-01 00:00:00

  • Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma after failure of the LNH 84 regimen.

    abstract::We assessed the efficacy of an etoposide, ifosfamide and methotrexate combination therapy (VIM) in 24 patients failing the LNH 84 protocol. Eight of these patients were refractory to the LNH 84 induction regimen, 10 were partial responders and the six remaining attained complete response after LNH 84 induction but rel...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1002/hon.2900090411

    authors: Herbrecht R,Ortiz S,Damonte JC,Liu KL,Maloisel F,Dufour P,Bergerat JP,Oberling F

    更新日期:1991-07-01 00:00:00

  • Langerhans cell histiocytosis with central nervous system involvement--complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib.

    abstract::Langerhans cell histiocytosis (LCH) is rare in adults, and only a subset of these patients suffers from central nervous system (CNS) involvement. Hence, evidence-based treatment recommendations are lacking. A case of a 20-year-old student with multisystem LCH and extensive CNS involvement is described, who showed a du...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.1005

    authors: Baumann M,Cerny T,Sommacal A,Koeberle D

    更新日期:2012-06-01 00:00:00

  • Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology.

    abstract::B-cell post-transplant lymphoproliferative disorders (PTLD) are classified as early lesions, polymorphic lymphomas (P-PTLD) and monomorphic lymphomas (M-PTLD). These morphologic categories are thought to reflect a biologic continuum, although supporting genetic data are lacking. To gain better insights into PTLD patho...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.859

    authors: Vakiani E,Basso K,Klein U,Mansukhani MM,Narayan G,Smith PM,Murty VV,Dalla-Favera R,Pasqualucci L,Bhagat G

    更新日期:2008-12-01 00:00:00

  • Retinoblastoma protein and Epstein-Barr virus (EBV) expression in South African Hodgkin's disease.

    abstract::The aim of this study was to explore the expression of retinoblastoma protein and EBV status in a cohort of cases of Hodgkin's disease from South Africa. Seventy one cases of Hodgkin's disease were accessed over a 6-year period and were classified according to the Rye Classification. Relevant sections were stained wit...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/(sici)1099-1069(199711)15:4<191::aid-hon61

    authors: Chetty R,Bickhoo A

    更新日期:1997-11-01 00:00:00

  • Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade.

    abstract::Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Survival has improved over the last several decades, mainly because of the incorporation of the anti-CD20 antibody rituximab into preexisting or rediscovered agents. The disease has a relapsing and remitting pattern, coupled with a risk of transform...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2711

    authors: Apostolidis J,Mokhtar N,Al Omari R,Darweesh M,Al Hashmi H

    更新日期:2020-08-01 00:00:00

  • Consolidation with 90 Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma.

    abstract::Bendamustine and rituximab (BR) are widely used in patients with follicular lymphoma (FL) previously treated with conventional immunochemotherapy, but the role of consolidation radioimmunotherapy in these patients is unknown. This study evaluated the efficacy and safety of consolidation with 90 Yttrium-ibritumomab tiu...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2809

    authors: Miura K,Tsujimura H,Masaki Y,Iino M,Takizawa J,Maeda Y,Yamamoto K,Tamura S,Yoshida A,Yagi H,Yoshida I,Kitazume K,Masunari T,Choi I,Kakinoki Y,Suzuki R,Yoshino T,Nakamura S,Hatta Y,Yoshida T,Kanno M

    更新日期:2020-09-25 00:00:00

  • Comparison of 60 and 80 mg/m2 of daunorubicin in induction therapy of acute myeloid leukaemia.

    abstract::For finding better method of acute myeloid leukaemia (AML) induction, we designed a prospective clinical trial to find a more effective regimen with least toxicity for induction therapy of AML. Hence, we examined different accepted doses of daunorubicin and their outcomes. Total of 114 patients were included in the st...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.2236

    authors: Vaezi M,Bahar B,Mousavi A,Yaghmai M,Kasaeian A,Souri M,Jahani M,Alimoghaddam K,Ghavamzadeh A

    更新日期:2017-03-01 00:00:00

  • The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation.

    abstract::Dapsone is commonly used for pneumocystis carinii pneumonia (PCP) prophylaxis in immunocompromised patients. It has been used as an alternative therapy in the hematopoietic stem cell transplant (HSCT) setting in patients who can't tolerate trimethoprim-sulfamethoxazole. The Sulfone syndrome is not a well-known sequela...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.780

    authors: Abidi MH,Kozlowski JR,Ibrahim RB,Peres E

    更新日期:2006-09-01 00:00:00

  • Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome.

    abstract::Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive factors and outcome of refractoriness to first-line ICT. All patients diagnosed wi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2378

    authors: Sorigue M,Mercadal S,Alonso S,Fernández-Álvarez R,García O,Moreno M,Pomares H,Alcoceba M,González-García E,Motlló C,González-Barca E,Martin A,Sureda A,Caballero D,Ribera JM,Sancho JM

    更新日期:2017-12-01 00:00:00

  • Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study.

    abstract::This is a phase II study of panobinostat, an oral pan-HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28-day cycle. Rituximab was administered weekly during the first cycle, then on Day 1 of cycle...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2515

    authors: Barnes JA,Redd R,Fisher DC,Hochberg EP,Takvorian T,Neuberg D,Jacobsen E,Abramson JS

    更新日期:2018-10-01 00:00:00

  • Primary bone marrow lymphoma is a rare neoplasm with poor outcome: case series from single tertiary care centre and review of literature.

    abstract::Primary bone marrow lymphoma is a rare disease and remains undiagnosed due to deceptive clinical presentation. Here, we report four cases of primary bone marrow B-cell non-Hodgkin lymphoma, which presented with cytopenias without any lymphadenopathy or organomegaly. Bone marrow examination revealed large atypical B-ce...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2178

    authors: Bhagat P,Sachdeva MU,Sharma P,Naseem S,Ahluwalia J,Das R,Varma N,Law A,Malhotra P

    更新日期:2016-03-01 00:00:00

  • The relation between hypocholesterolemia and degree of maturation in acute myeloid leukemia.

    abstract::Plasma cholesterol concentrations were determined in 83 acute myeloid leukemia patients. Mean plasma cholesterol concentration (+/- S.D.) at the time of diagnosis was 2.91 mmol/L (+/- 1.13). The percentage of AML patients having hypocholesterolemia was 90.4 per cent. The lowest cholesterol levels were observed in the ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900080109

    authors: Zyada LE,Hassan HT,Rees JK,Ragab MH

    更新日期:1990-01-01 00:00:00

  • Characterization of myeloid leukemias with monoclonal antibodies 3C5 and MY9.

    abstract::The expression of two membrane antigens identified by the monoclonal antibodies (McAb) My9 and 3C5 has been investigated in cells from 80 acute leukemias. My9 was positive in the blasts of 33 out of the 38 (87 per cent) cases of acute myeloid leukemia (AML) tested, regardless of FAB subtype, and in 13 of 18 (72 per ce...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900030306

    authors: Matutes E,Rodriguez B,Polli N,Tavares de Castro J,Parreira A,Andrews C,Griffin JD,Tindle RW,Catovsky D

    更新日期:1985-07-01 00:00:00

  • Cytotoxic and DNA-inhibitory effects of iron chelators on human leukaemic cell lines.

    abstract::Cytotoxic and DNA synthesis inhibitory effects of several iron chelators with different physicochemical properties have been tested in four myeloid leukaemic cell lines (U937, K562, ML2 and HL60). The small lipophilic chelators 8-hydroxyquinoline, tropolone and omadine at 2 X 10(-5) M, caused substantial inhibition of...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900040303

    authors: Kontoghiorghes GJ,Piga A,Hoffbrand AV

    更新日期:1986-07-01 00:00:00

  • Cytokinetic study on the effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine on murine leukemic cells L 1210: a comparison with the effects of 1-beta-D-arabinofuranosylcytosine.

    abstract::The effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) on the cell cycle of murine leukemic cells (L 1210 cells) were compared with those of 1-beta-D-arabinofuranosylcytosine (ara-C), known to be effective for acute leukemia. In a cytokinetic study, a combination of Feulgen microcytofluorometry and triti...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900030106

    authors: Maruo N,Horiuchi H,Nakabo T,Kondo M,Nakamura T

    更新日期:1985-01-01 00:00:00

  • The more basic isoform of eEF1A relates to tumour cell phenotype and is modulated by hyper-proliferative/differentiating stimuli in normal lymphocytes and CCRF-CEM T-lymphoblasts.

    abstract::The elongation factor 1A proteins (eEF1A1/A2) are known to play a role in tumours. We previously found that a more basic isoform of eEF1A (MBI-eEF1A) is present in the cytoskeletal/nuclear-enriched extracts of CCRF-CEM T-lymphoblasts but not in those of normal lymphocytes. To obtain deeper knowledge about MBI-eEF1A bi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2022

    authors: Scaggiante B,Dapas B,Pozzato G,Grassi G

    更新日期:2013-06-01 00:00:00

  • Evidence for the detection of the normal counterpart of Hodgkin and Sternberg-Reed cells.

    abstract::To clarify the origin of Hodgkin (H) and Sternberg-Reed (SR) cells, frozen sections of lymph nodes from 30 patients with Hodgkin's disease were immunostained with a large panel of monoclonal antibodies reactive with cells of lymphoid tissue and granulopoiesis. The results showed that: (a) H and SR cells are devoid of ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900010105

    authors: Stein H,Gerdes J,Schwab U,Lemke H,Diehl V,Mason DY,Bartels H,Ziegler A

    更新日期:1983-01-01 00:00:00

  • Acute myeloid leukemia in elderly adults.

    abstract::One hundred and fifteen previously untreated adults aged over 60 years were referred to St Bartholomew's Hospital between 1978 and 1986 for management of acute myeloid leukemia (AML). Twenty-seven patients received symptomatic or palliative treatment only because combination chemotherapy was considered inappropriate. ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900080103

    authors: Tucker J,Thomas AE,Gregory WM,Ganesan TS,Malik ST,Amess JA,Lim J,Willis L,Rohatiner AZ,Lister TA

    更新日期:1990-01-01 00:00:00

  • First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.

    abstract::During the formation of the Philadelphia (Ph) chromosome, in the majority of chronic myelogenous leukemia (CML) patients, the chromosome 22 breakpoint is located in the major breakpoint cluster region of the BCR gene (M-bcr). Minor and micro breakpoint cluster regions (m-bcr with e1a2 transcript and micro-bcr with e19...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.822

    authors: Andrikovics H,Nahajevszky S,Szilvási A,Bors A,Adám E,Kozma A,Kajtár B,Barta A,Poros A,Tordai A

    更新日期:2007-09-01 00:00:00

  • Cytogenetics and molecular genetics of childhood leukemia.

    abstract::Childhood leukemia is the commonest form of childhood cancer and represents clonal proliferation of transformed hemopoietic cells as a result of genetic changes. Molecular characterization of these changes, in particular chromosomal translocations, has yielded a wealth of information on the mechanisms of leukemogenesi...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/(sici)1099-1069(199909)17:3<91::aid-hon643

    authors: Ma SK,Wan TS,Chan LC

    更新日期:1999-09-01 00:00:00

  • Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.

    abstract::Continuous administration of amphotericin B deoxycholate over 24 hours (24 h-D-AmB) is better tolerated than rapid infusions. However, toxicity and outcome have not been assessed in a homogenous patient population with acute myeloid leukaemia (AML). We retrospectively analysed renal function and outcome in all adult p...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2500

    authors: Rothenbühler C,Held U,Manz MG,Schanz U,Gerber B

    更新日期:2018-04-01 00:00:00

  • Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: Association with chronic graft-versus-host disease and survival outcome.

    abstract::Delayed platelet recovery (DPR) despite prompt neutrophil engraftment is frequently observed after allogeneic hematopoietic stem cell transplantation (HSCT). However, few studies have evaluated the risk factors and long-term outcome. Therefore, we retrospectively analysed 219 adult patients who underwent their first a...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2427

    authors: Akahoshi Y,Kimura SI,Gomyo A,Hayakawa J,Tamaki M,Harada N,Kusuda M,Kameda K,Ugai T,Wada H,Ishihara Y,Kawamura K,Sakamoto K,Sato M,Terasako-Saito K,Kikuchi M,Nakasone H,Kako S,Kanda Y

    更新日期:2018-02-01 00:00:00

  • Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis.

    abstract::The aim of this article is to meta-analyse published data about the detection rate (DR) of fluorine-18-fluorodeoxyglucose ((18) F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) in the evaluation of patients with marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT). A compreh...

    journal_title:Hematological oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1002/hon.2152

    authors: Treglia G,Zucca E,Sadeghi R,Cavalli F,Giovanella L,Ceriani L

    更新日期:2015-09-01 00:00:00